HALLE (SAALE) / MUNICH, GERMANY, 14 December 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; ISIN DE0007921835) has been informed by Hauck & Aufhäuser Privatbankiers AG […]
HALLE (SAALE) / MUNICH, Germany, 30 November 2020 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announced today that it has completed its conversion into an N.V., a […]
HALLE (SAALE) / MUNICH, Germany, 26 November 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN DE0007921835) announced today its third quarter business update for the period […]
HALLE (SAALE) / MUNICH, Germany, 19 November 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), a biotechnology company focused on developing first-in-class therapeutics targeting post-translational modifying […]
All proposed resolutions approved with large majority HALLE (SAALE) / MUNICH, Germany, 01 October 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today […]
HALLE (SAALE) / MUNICH, GERMANY, 3 September 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) invites all shareholders to Vivoryon Therapeutics´ ordinary general meeting of […]
Vivoryon Therapeutics intends the transfer of the statutory seat to Amsterdam, the Netherlands, leading to a conversion into a public company under the laws of the […]
Conference call and webcast in English at 3:00 pm CEST / 09:00 am EDT Vivoryon and Nordic Bioscience collaboration Meprin protease inhibitors development program HALLE (SAALE) / […]
HALLE (SAALE) / MUNICH, Germany, 20 August 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), will publish its Half Year Results for 2020 on Thursday, August 27, […]